Amanda J. Wheeler

Amanda J. Wheeler

Auto-generated profile, based on publicly available information

Amanda J. Wheeler

Centre for Mental Health, Griffith University, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Health Expectations
Verified
Journal Article
Closed access
PDF file
Adem SavAdem Sav
Adem Sav
MKMichelle A. King
Michelle A. King
JWJennifer A. Whitty
Jennifer A. Whitty
EKElizabeth Kendall
Elizabeth Kendall
SMSara McMillan
Sara McMillan
AWAmanda J. Wheeler
Amanda J. Wheeler

25 July 2014 in Health Services and Outcomes Research Methodology
Verified
Journal Article
Closed access
PDF file
SMSara McMillan
Sara McMillan
FKFiona Kelly
Fiona Kelly
Adem SavAdem Sav
Adem Sav
EKElizabeth Kendall
Elizabeth Kendall
MKMichelle A. King
Michelle A. King
AWAmanda J. Wheeler
Amanda J. Wheeler

26 July 2013 in Medical Care Research and Review
Verified
Journal Article
Closed access
SMSara McMillan
Sara McMillan
EKElizabeth Kendall
Elizabeth Kendall
Adem SavAdem Sav
Adem Sav
MKMichelle A. King
Michelle A. King
JWJennifer A. Whitty
Jennifer A. Whitty
AWAmanda J. Wheeler
Amanda J. Wheeler
There is growing interest in patient-centered care, but there is little guidance about the interventions required for its delivery and whether it leads to better health outcomes. This systematic review evaluates the efficacy of patient-centered care interventions for people with chronic conditions. Thirty randomized controlled trials were identified from health-related databases. The findings indicated that most interventions were based on the notion of empowering care and included attempts to educate consumers or prompt them about how to manage a health consultation. Other common interventions focused on training providers in delivering empowering care. Although it was difficult to draw firm conclusions because of the moderate to high risk of bias of the research designs, this review has shown some promising findings from implementing a patient-centered care approach. There appeared to be benefits associated with this model of care in terms of patient satisfaction and perceived quality of care.

23 May 2013 in Health & Social Care in the Community
Verified
Journal Article
Closed access
PDF file
Adem SavAdem Sav
Adem Sav
EKElizabeth Kendall
Elizabeth Kendall
SMSara McMillan
Sara McMillan
FKFiona Kelly
Fiona Kelly
JWJennifer A. Whitty
Jennifer A. Whitty
AWAmanda J. Wheeler
Amanda J. Wheeler
The aim of this study was to explore treatment burden among people with a variety of chronic conditions and comorbidities and their unpaid carers. The burden of living with ongoing chronic illness has been well established. However, the burden associated with proactively treating and managing chronic illness, commonly referred to as ‘treatment burden’, is less understood. This study helps to bridge this gap in our understanding by providing an in-depth analysis of qualitative data collected from a large sample of adults from diverse backgrounds and with various chronic conditions. Using semi-structured in-depth interviews, data were collected with a large sample of 97 participants that included a high representation of people from culturally and linguistically diverse backgrounds and indigenous populations across four regions of Australia. Interviews were conducted during May–October 2012, either face to face (n = 49) or over the telephone (n = 48) depending on the participant's preference and location. Data were analysed using an iterative thematic approach and the constant comparison method. The findings revealed four interrelated components of treatment burden: financial burden, time and travel burden, medication burden and healthcare access burden. However, financial burden was the most problematic component with the cost of treatment being significant for most people. Financial burden had a detrimental impact on a person's use of medication and also exacerbated other types of burden such as access to healthcare services and the time and travel associated with treatment. The four components of treatment burden operated in a cyclical manner and although treatment burden was objective in some ways (number of medications, and time to access treatment), it was also a subjective experience. Overall, this study underscores the urgent need for healthcare professionals to identify patients overwhelmed by their treatment and develop ‘individualised’ treatment options to alleviate treatment burden.

22 April 2008 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
AWAmanda J Wheeler
Amanda J Wheeler
Objective: To describe the treatment pathway and patterns of clozapine use in patients with schizophrenia, including coprescribed psychotropic medications, and compare the extent of coprescribing of clozapine with that of non-clozapine schizophrenia treatment in community montal health services in the Auckland and Northland regions of New Zealand. Methods: A retrospective chart review was conducted for adult outpatients receiving care from community mental health services on October 31, 2004. Data collected for all patients prescribed an antipsychotic included demographics (sex, age, ethnicity); principal diagnosis (Diagnostic and Statistical Manual of Mental Disorders, 4th edition); comorbid conditions; duration of mental illness; psychiatric admissions; and treatment information (psychotropic medications, with dose and route of administration). If clozapine had been started after the introduction of full government prescription subsidy (February 1999), additional data, including year of initiation and prior antipsychotic history, were collected. Analysis included all outpatients with a diagnosis of schizophrenia (including schizoaffective disorder). Results: Antipsychotics were prescribed for 2796 schizophrenia patients; 32.8% were prescribed clozapine, with a mean dose of 372 mg/day and an average duration of illness of 9.7 years before starting clozapine. Patients who had started treatment after clozapine was funded by the government (59.3%) had received a median of 3 antipsychotic drugs prior to starting clozapine; most of the treatment regimens included 1 second-generation antipsychotic (91.2%). Clozapine patients were less likely to be coprescribed another antipsychotic compared with non-clozapine patients (11.7% vs 17.6%; p conclusions: Outpatients with treatment-resistant schizophrenia were prescribed clozapine at expected rates; however, treatment was delayed longer than recommended. There is some evidence that access to clozapine for treatment-resistant schizophrenia has improved, possibly as the result of the introduction of government subsidy, guideline dissemination, or increasing experience of clinicians with use of clozapine. In this real-world environment, the number of concomitant psychotropic medications for outpatients with schizophrenia was found to be low; when used concomitantly with clozapine, they were most commonly used to manage adverse effects.

1 June 2018 in Australian Prescriber
Verified
Journal Article
Open access
PDF file
AWAmanda J Wheeler
Amanda J Wheeler
SSShane Scahill
Shane Scahill
DHDavid Hopcroft
David Hopcroft
HSHelen Stapleton
Helen Stapleton
Medication errors are common when people move between different parts of the health system. How can mistakes be avoided?